No phaseRecruiting
Thrombocytopenia Trajectories in Antiphospholipid Syndrome: A Multicenter Cohort Study
Thrombocytopenia Trajectories as a Dynamic Biomarker of Clinical Severity and Survival in Antiphospholipid Syndrome: A Multicenter Cohort Study
- Sponsor
- New Valley University (Academic or other)
- Enrollment
- 200 planned
- Conditions
- Antiphospholipid Syndrome
- Interventions
- Platelet count
- Ages
- adults, older adults
- Registry
- NCT07757789
Full record on ClinicalTrials.gov
From the registry
Thrombocytopenia is common in antiphospholipid syndrome (APS) and is now included in the 2023 ACR/EULAR APS criteria as an important non criteria/hematologic feature. Persistent or low-moderate thrombocytopenia independently predicts reduced long-term survival in APS, with hazard ratios for mortality around 2.7-4.4, and is associated with a severe disease phenotype and thrombotic deaths.
Primary outcomes
- All-cause mortality
History
Study completion expected
Primary completion expected
Last registry update
Registered
Started